AVVA’s knowledge and research on the microbiota’s self-regulating properties and competitive inhibition of pathogenic bacteria by the symbiotic ones, has led to the development of combinations consisting of antimycotic and prebiotic, targeted to enhance the treatment outcome of candidal vulvovaginitis (vaginal trush).

Ecofucin is a new combination of natamycin and lactulose proven to increase the therapeutic potential compared to natamycin as a monotherapy.

This combination essentially incorporates a dual mechanism of action, the antimycotic effect of natamycin with prebiotic’s bifidogenic effect that stimulates the innate mechanism of competitive inhibition of pathogenic microorganisms by Lactobacilli and Bifidobacteria.